JP Stock MarketDetailed Quotes
4502 Takeda Pharmaceutical
- 4130.0
- -8.0-0.19%
20min DelayMarket Closed May 17 15:00 JST
6.48TMarket Cap45.30P/E (Static)
4158.0High4105.0Low3.24MVolume4150.0Open4138.0Pre Close13.38BTurnover4873.052wk High0.21%Turnover Ratio1.57BShares3900.052wk Low91.16EPS TTM6.28TFloat Cap8080.0Historical High45.30P/E (Static)1.52BShs Float2894.5Historical Low91.16EPS LYR1.28%Amplitude188.00Dividend TTM0.89P/B100Lot Size4.55%Div YieldTTM
About Takeda Pharmaceutical Company
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Company Profile
Symbol4502
Company NameTakeda Pharmaceutical
Founded1925-01-29
MarketTSE Prime
Employees49095
Fiscal Year Ends03-31
Address1-1, Nihonbashi-Honcho 2-Chome Chuo-ku
Zip Code540-8645
Phone06-6204-2111
Websitewww.takeda.com
Company Executives
- Name
- Position
- Salary
- Christophe Weber
- Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.A., Inc.
- 1.72B
- Gabriele Ricci
- Chief Data and Technology Officer
- --
- Costa Saroukos
- Director and Chief Financial Officer
- 2.49B
- Lauren Duprey
- Chief Human Resources Officer
- --
- Mwana Lugogo
- Chief Ethics and Compliance Officer
- --
- Takako Ohyabu
- Chief Global Corporate Affairs and Sustainability Officer
- --
- Marcello Agosti
- Global Business Development Officer
- --
- Koki Sato
- Corporate Strategy Officer
- --
- Dr. Thomas Wozniewski, PhD
- Global Manufacturing and Supply Officer
- --
- Milano Furuta
- President, Japan Pharma Business Unit
- --
- Teresa Bitetti
- President, Global Oncology Business Unit
- --
- Masami Iijima
- Chairman of the Board
- 43.00M
- Giles Platford
- President, Plasma-Derived Therapies Business Unit
- --
- Andrew S. Plump, M.D.
- Director and President, Research and Development
- 972.00M
- Ramona Sequeira
- President, Global Portfolio Division
- --
- Julie Kim
- President, U.S. Business Unit and U.S. Country Head
- --
- Michel Orsinger
- Independent Director
- 39.00M
- Dr. John M. Maraganore,PhD
- Independent Director
- 32.00M
- Miki Tsusaka
- Independent Director
- --
- Kimberly A. Reed
- Independent Director
- 34.00M
- Koji Hatsukawa
- Independent Director
- 43.00M
- Yoshiaki Fujimori
- Independent Director
- 41.00M
- Dr. Steven Gillis, Pd.D
- Independent Director
- 38.00M
- Olivier Bohuon
- Independent Director
- 38.00M
- Jean-Luc Butel
- Independent Director
- 38.00M
- Ian T. Clark
- Independent Director
- 38.00M
- Emiko Higashi
- Independent Director
- 43.00M
- Yoshihiro Nakagawa
- Global General Counsel
- --
Analysis
Price Target
No Data
Heat List
JP
Overall
Symbol
Latest Price
%Chg